Physician profile
Ryan Little
NPI 1215098025
$17,704.64
in general payments reported to CMS, 2019-2025
43 companies · $4,844 in 2025
The $4,844 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,690 · 2022: $2,810 · 2023: $3,236 · 2024: $4,125 · 2025: $4,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,205.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,636.36 | 2021-2025 | |
| Novo Nordisk INC | $3,010.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $1,978.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,264.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,045.11 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Viiv Healthcare Company | $962.24 | 2021-2025 | Dovato |
| Lilly USA, LLC | $660.50 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $551.87 | 2021-2025 | Repatha, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $463.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.28 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $354.92 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $322.60 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $305.31 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $258.38 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.78 | 2025 | Caplyta |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $233.27 | 2022-2024 | Xarelto |
| Antares Pharma, INC. | $218.08 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| E.R. Squibb & Sons, L.L.C. | $185.90 | 2022-2024 | Eliquis, Camzyos |
| Neurocrine Biosciences, INC. | $160.63 | 2023-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $159.00 | 2023-2025 | Gardasil 9, Capvaxive, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.90 | 2021-2025 | Xifaxan, Relistor |
| Axsome Therapeutics, INC. | $125.98 | 2023-2025 | Auvelity |
| Corcept Therapeutics | $116.85 | 2023 | Korlym |
| Verona Pharma, INC. | $111.05 | 2025 | Ohtuvayre |
| Corium, LLC | $107.77 | 2023 | Azstarys |
| Astellas Pharma US INC | $90.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.41 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $81.07 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $76.20 | 2023-2024 | |
| Lundbeck LLC | $50.75 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.21 | 2022 | |
| Halozyme INC | $39.41 | 2023 | |
| Emd Serono, INC. | $37.12 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $31.00 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2023 | Trintellix |
| Optinose US, INC. | $17.31 | 2021 | |
| Novavax INC | $17.05 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Xeris Pharmaceuticals, INC. | $16.28 | 2023 | Gvoke Hypopen |
| Braeburn INC. | $16.07 | 2025 | Brixadi |
| Indivior INC. | $15.60 | 2023 | Sublocade |
| Idorsia Pharmaceuticals US INC | $14.89 | 2022 | |
| Ibsa Pharma INC. | $14.62 | 2025 | Licart, Flector, Tirosint |
| Tolmar, INC. | $13.78 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.